What is Neurocrine Biosciences' stock symbol?
Neurocrine Biosciences trades on the NASDAQ under the ticker symbol "NBIX."
Where is Neurocrine Biosciences' stock going? Where will Neurocrine Biosciences' stock price be in 2017?
15 brokerages have issued twelve-month target prices for Neurocrine Biosciences' shares. Their predictions range from $55.00 to $100.00. On average, they expect Neurocrine Biosciences' stock price to reach $67.23 in the next year.
When will Neurocrine Biosciences announce their earnings?
Neurocrine Biosciences is scheduled to release their next quarterly earnings announcement on Wednesday, May, 3rd 2017.
What are analysts saying about Neurocrine Biosciences stock?
Here are some recent quotes from research analysts about Neurocrine Biosciences stock:
Cowen and Company analysts commented, "NBIX remains well funded, ending Q4 with $352MM in cash." (2/15/2017)
- Robert W. Baird analysts commented, "No change to outlook heading into Ingrezza approval. Neurocrine reported a solid end to the year, modestly beating estimates on lower-than-expected opex. Though we are only a few weeks into 2017, it has already been a busy year for NBIX. Expect the year to continue to bring multiple updates, from potential approval of Ingrezza in TD and Tourette data in May to Phase 3 UF data for elagolix near year-end, an elagolix NDA submission, advances in CAH and essential tremor, and FDA discussions on newly licensed opicapone' Earnings and spend in-line, expect accelerations into launch. 4Q16 EPS of ($0.51) modestly beat our/consensus estimates of ($0.54)/($0.57), respectively, due to lower than projected operating expenses. Looking ahead to 2017, management expects opex to increase to about $230M-$240M due activities surrounding the launch of Ingrezza." (2/15/2017)
- Needham & Company LLC analysts commented, "Company continues to prepare for Ingrezza launch ahead of 4/11/17 PDUFA date. We expect approval based on strength of Phase 3 data, followed by launch ~6wks later. We believe Boxed Warning/ REMS are possible. Phase 2 pediatric Tourette Syndrome (TS) data are expected May 2017 (was Apr). Given efficacy trend observed in adult Phase 2 TS, we believe Ingrezza will likely be active in pediatric TS as well. Elagolix NDA submission for Endometriosis by Abbvie is expected 3Q17 (was 2H17), triggering a $30M payment to Neurocrine. Phase 3 results in Uterine Fibroids are expected by YE17. We believe stock is attractive ahead of near term events. BUY." (2/10/2017)
HC Wainwright analysts commented, "We expect FDA to agree in early 2017 that Atara has demonstrated comparability between clinical batches of ATA-129, or EBV-CTL, and the prior material produced at MSKCC, paving the way for Phase 3 start. We believe comparability data will include the number of cells to administer, cytoreactivity, cell storage time, restriction studies (HLA types), variability based on release criteria, and the methods by which data are collected. CMC amendment standard for new clinical material Importantly, a CMC amendment is standard practice for an IND when new clinical material is introduced; therefore, we view Atara’s process as normal." (1/18/2017)
- Jefferies Group LLC analysts commented, "While the study showed a stat sig improvement on the Clinical Global Impression of Change scale (CGI; p=0.015), the study did not reach stat sig on the 1EP of Yale Global Tic Severity Scale (YGTSS; p=0.18). No further trial details were released. Although a setback, we note that this does not directly read through to the pediatric study readout expected in April." (1/18/2017)
Who owns Neurocrine Biosciences stock?
Neurocrine Biosciences' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include FMR LLC (14.91%), Perceptive Advisors LLC (3.82%), Franklin Resources Inc. (2.77%), Janus Capital Management LLC (2.71%), State Street Corp (2.64%) and Orbimed Advisors LLC (2.45%). Company insiders that own Neurocrine Biosciences stock include Christopher Flint Obrien, Corinne H Nevinny, Darin Lippoldt, Dimitri E Grigoriadis, Gary A Lyons, Haig P Bozigian, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith, Richard F Pops, Timothy P Coughlin, W Thomas Mitchell and William H Rastetter.
Who sold Neurocrine Biosciences stock? Who is selling Neurocrine Biosciences stock?
Neurocrine Biosciences' stock was sold by a variety of institutional investors in the last quarter, including Asset Management One Co. Ltd., AQR Capital Management LLC, FMR LLC, Guggenheim Capital LLC, GRT Capital Partners L.L.C., Allianz Asset Management AG, RidgeWorth Capital Management LLC and Loomis Sayles & Co. L P. Company insiders that have sold Neurocrine Biosciences stock in the last year include Christopher Flint Obrien, Corinne H Nevinny, Dimitri E Grigoriadis, Haig P Bozigian, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith, Richard F Pops, Timothy P Coughlin and William H Rastetter.
Who bought Neurocrine Biosciences stock? Who is buying Neurocrine Biosciences stock?
Neurocrine Biosciences' stock was acquired by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Franklin Resources Inc., Orbimed Advisors LLC, Janus Capital Management LLC, Alyeska Investment Group L.P., State Street Corp, Marshall Wace LLP and Two Sigma Investments LP.
How do I buy Neurocrine Biosciences stock?
Shares of Neurocrine Biosciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Neurocrine Biosciences stock cost?
One share of Neurocrine Biosciences stock can currently be purchased for approximately $42.72.